Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

A GPCR goal
September 2020
SHARING OPTIONS:

TOKYO & LONDON—This summer saw the beginning of an exclusive discovery collaboration and option-to-license agreement between Sosei Group Corporation and AbbVie for the discovery, development and commercialization of novel medicines for G protein-coupled receptor (GPCR) targets. Initial work will be centered on novel small molecules for treating inflammatory and autoimmune diseases. Per the agreement, Sosei Heptares stands to receive up to $32 million in upfront and near-term milestone payments, as well as up to $377 million in potential option, development and commercial milestones. Sosei Heptares is also eligible for tiered royalties on global sales. For its part, AbbVie will have the option of expanding this agreement to a total of four targets. Sosei Heptares will apply its StaR technology and structure-based drug design capabilities and fund R&D activities through the completion of IND-enabling studies, at which point AbbVie can then pay license fees to exercise it options and assume responsibility for global development and commercialization.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.